These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 14570880)

  • 1. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.
    Arlander SJ; Eapen AK; Vroman BT; McDonald RJ; Toft DO; Karnitz LM
    J Biol Chem; 2003 Dec; 278(52):52572-7. PubMed ID: 14570880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
    Mesa RA; Loegering D; Powell HL; Flatten K; Arlander SJ; Dai NT; Heldebrant MP; Vroman BT; Smith BD; Karp JE; Eyck CJ; Erlichman C; Kaufmann SH; Karnitz LM
    Blood; 2005 Jul; 106(1):318-27. PubMed ID: 15784732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
    Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
    Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells.
    Giessrigl B; Krieger S; Rosner M; Huttary N; Saiko P; Alami M; Messaoudi S; Peyrat JF; Maciuk A; Gollinger M; Kopf S; Kazlauskas E; Mazal P; Szekeres T; Hengstschläger M; Matulis D; Jäger W; Krupitza G
    Hum Mol Genet; 2012 Nov; 21(21):4615-27. PubMed ID: 22843495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
    Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
    Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
    Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
    Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.
    Ewald B; Sampath D; Plunkett W
    Mol Cancer Ther; 2007 Apr; 6(4):1239-48. PubMed ID: 17406032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
    Münster PN; Basso A; Solit D; Norton L; Rosen N
    Clin Cancer Res; 2001 Aug; 7(8):2228-36. PubMed ID: 11489796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.
    Yao Q; Weigel B; Kersey J
    Clin Cancer Res; 2007 Mar; 13(5):1591-600. PubMed ID: 17332306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.
    Castro JE; Prada CE; Loria O; Kamal A; Chen L; Burrows FJ; Kipps TJ
    Blood; 2005 Oct; 106(7):2506-12. PubMed ID: 15972449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
    da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R
    Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.
    Demidova AR; Aau MY; Zhuang L; Yu Q
    J Biol Chem; 2009 Feb; 284(7):4132-9. PubMed ID: 19060337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.
    Karnitz LM; Flatten KS; Wagner JM; Loegering D; Hackbarth JS; Arlander SJ; Vroman BT; Thomas MB; Baek YU; Hopkins KM; Lieberman HB; Chen J; Cliby WA; Kaufmann SH
    Mol Pharmacol; 2005 Dec; 68(6):1636-44. PubMed ID: 16126823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
    Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK
    Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.
    Sain N; Krishnan B; Ormerod MG; De Rienzo A; Liu WM; Kaye SB; Workman P; Jackman AL
    Mol Cancer Ther; 2006 May; 5(5):1197-208. PubMed ID: 16731752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
    Guzi TJ; Paruch K; Dwyer MP; Labroli M; Shanahan F; Davis N; Taricani L; Wiswell D; Seghezzi W; Penaflor E; Bhagwat B; Wang W; Gu D; Hsieh Y; Lee S; Liu M; Parry D
    Mol Cancer Ther; 2011 Apr; 10(4):591-602. PubMed ID: 21321066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
    Yin X; Zhang H; Burrows F; Zhang L; Shores CG
    Clin Cancer Res; 2005 May; 11(10):3889-96. PubMed ID: 15897590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.
    Pedersen KS; Kim GP; Foster NR; Wang-Gillam A; Erlichman C; McWilliams RR
    Invest New Drugs; 2015 Aug; 33(4):963-8. PubMed ID: 25952464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.